The Botulinum Journal
- Editor in Chief
- Dr. M.A. Dorgham
- ISSN online
- ISSN print
- 4 issues per year
Botulinum neurotoxins are a unique group of proteins, with extreme biological activities in areas such as toxins, therapeutics and cosmetics. Clostridium botulinum has become a source of bioterror and beauty, both being pursued simultaneously for scientific development to counter the former while promoting the latter. TBJ provides an international forum and authoritative source of information encompassing varied fields, including microbiology, biochemistry, biophysics, biotechnology, proteomics, genomics, pharmacology, toxicology, drug development related to different forms/types of botulinum neurotoxins, and also Clostridium botulinum.
Topics covered include
- Origin and microbiology
- Genomics and structure
- Mode of action
- Biochemistry and host response
- The botulism disease and treatment, incl. case studies/epidemiology
- Botulinum as a weapon and protection
- Characterisation and antidote developments
- Basis of therapeutic uses of botulinum
- Diseases under treatment
- Research on currently available pharmaceutical products
- New applications/development of therapeutics
- Botulinum as a cosmeceutical
The objectives of TBJ are to disseminate knowledge, to provide a learned reference in the field, and to establish channels of communication amongst academics, medical and public health research experts, the pharmaceutical industry, the cosmetics industry, policy makers, and executives in industry, commerce and investment institutions. TBJ provides a forum to exchange scholarly ideas relevant to health, science, application and regulatory issues related to the botulinum neurotoxin and Clostridium botulinum.
- Professionals in medicine, the pharmaceutical industry and the cosmetics industry
- Academics involved and interested in teaching and research in the fundamental as well as applied aspects of botulinum and Clostridium botulinum
- Government researchers involved in developing countermeasures against botulinum threat, and involved in safe use of botulinum as therapeutics
- Industry researchers interested in developing new products based on botulinum neurotoxin
- Policy makers involved in biodefense, homeland security, public safety, and regulatory compliance
- General public interested in the use of botulinum-based pharmaceuticals and cosmeceuticals
TBJ publishes original and review papers, commentaries, technical reports, analytical models, mathematical simulations, case studies, conference reports, book reviews, notes, managerial and policy issues and news. Contributions may be by submission or invitation, and suggestions for Special Issues and publications are welcome.
Editor in Chief
- Dorgham, M.A., International Centre for Technology and Management, UK
- Adler, Michael, U.S. Army Medical Research Institute of Chemical Defense, USA
- Jankovic, Joseph, Baylor College of Medicine, USA
Editorial Board Members
- Aoki, Roger, Allergan, USA
- Borodic, Gary E., Harvard Medical School, USA
- Brunger, Axel, Stanford University, USA
- Dhaked, Ram Kumar, Defence Research and Development Establishment (DRDE), India
- Dolly, J. Oliver, Dublin City University, Ireland
- Dressler, Dirk, Hannover Medical School, Germany
- Hall, Robert, National Institute of Allergy and Infectious Diseases, USA
- Janda, Kim D., Scripps Research Institute, USA
- Johnson, Eric A., Food Research Institute, USA
- Keller, James, Food and Drug Administration, USA
- Lebeda, Frank, USAMRIID, USA
- McArdle, Joseph J., UMDNJ - New Jersey Medical School, USA
- Millard, Charles B., Walter Reed Army Institute of Research, USA
- Minton, Nigel P., University of Nottingham, UK
- Moore, Austen Peter, The Walton Centre for Neurology and Neurosurgery NHS Trust, UK
- Oguma, K., Okayama University Medical School, Japan
- Oyler, George, Synaptic Research LLC, USA
- Peck, Mike, Institute of Food Research, UK
- Poulain, Bernard, Institute for Cellular and Integrative Neurosciences, France
- Sesardic, Dorothea, National Institute for Biological Standards and Control, NIBSC, UK
- Sharma, Shashi K., US Food and Drug Administration, USA
- Shone, Clifford, Health Protection Agency, UK
- Smith, Leonard A., United States Army Medical Research Institute of Infectious Diseases, USA
- Swaminathan, Subramanyam, Brookhaven National Laboratory, USA
A few essentials for publishing in this journal
- Submitted articles should not have been previously published or be currently under consideration for publication elsewhere.
- Conference papers may only be submitted if the paper has been completely re-written (more details available here) and the author has cleared any necessary permissions with the copyright owner if it has been previously copyrighted.
- Briefs and research notes are not published in this journal.
- All our articles go through a double-blind review process.
- All authors must declare they have read and agreed to the content of the submitted article. A full statement of our Ethical Guidelines for Authors (PDF) is available.
- There are no charges for publishing with Inderscience, unless you require your article to be Open Access (OA). You can find more information on OA here.
- All articles for this journal must be submitted using our online submissions system.
- View Author guidelines.